AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.

The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients ...

One of the world’s biggest drug makers is suing the country’s smallest state. The argument is over a federal drug discount program ...

In victory for struggling medical providers, law protecting a federal drug discount program in RI goes into effect despite opposition from drugmakers ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

Participating hospitals in the Prime Vendor Program and the 340B program spent nearly $37.3 billion more on drugs from 2010 to 2021. Health care facilities participating in the Prime Vendor Program ...

A bipartisan group of lawmakers has sent a letter to the Department of Health and Human Services, asking the agency to cancel an upcoming rebate pilot for drugs purchased by hospitals under the 340B ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

The American Hospital Association says that the timing of drug companies' proposed 340B rebate model suggests a collective effort to undermine the program. The American Hospital Association (AHA) is ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

Pharmacy leaders are facing high-stakes challenges that could threaten the stability of drug access and affordability across the U.S. Amid this uncertainty, health systems are responding with urgency, ...

Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to cheaper medicines. But in practice the legislation would achieve the exact ...